Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Redefining cancer of unknown primary

Tony Greco • 9 Jun 2020
ASCO 2020
General Checkpoint Inhibitors Nivolumab

Tony Greco, MD, Tennessee Oncology, Nashville, TN, highlights the hot topics in cancer of unknown primary site, including liquid biopsies and immune checkpoint inhibitors, such as nivolumab. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Tony Greco

1:42
ADAURA: the benefit of adjuvant osimertinib
Tony Greco • 9 Jun 2020
4:01
Cancer of unknown primary: how did we get here?
Tony Greco • 9 Jun 2020

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
0:29
Innovative ctDNA-based liquid biopsy techniques for cancer diagnosis
Alain Thierry • 9 Apr 2024
0:50
Employing fragmentomics as a novel strategy to characterize and detect cancers
Alain Thierry • 9 Apr 2024
1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals